Stock Analysis on Net
Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

$24.99

Common-Size Income Statement
Quarterly Data

Paying user area

Try for free

Abbott Laboratories pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Abbott Laboratories, common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net sales
Cost of products sold, excluding amortization of intangible assets
Amortization of intangible assets
Gross profit
Research and development
Selling, general and administrative
Operating earnings
Interest expense
Interest income
Net foreign exchange gain (loss)
Net loss on extinguishment of debt
Other income (expense), net
Earnings from continuing operations before taxes
Taxes on earnings from continuing operations
Earnings from continuing operations
Net earnings from discontinued operations, net of tax
Net earnings

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Operating earnings The net result for the period of deducting operating expenses from operating revenues. Abbott Laboratories operating earnings as a percentage of net sales increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Earnings from continuing operations before taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Abbott Laboratories earnings from continuing operations before taxes as a percentage of net sales increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Net earnings The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Abbott Laboratories net earnings as a percentage of net sales increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.